Mva Investors, Llc Sells 110,731 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Mva Investors, Llc sold 110,731 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $8.87, for a total transaction of $982,183.97. Following the sale, the insider now owns 203,793 shares in the company, valued at $1,807,643.91. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Mva Investors, Llc also recently made the following trade(s):

• On Friday, June 28th, Mva Investors, Llc sold 29,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $8.57, for a total transaction of $248,530.00.
• On Thursday, June 6th, Mva Investors, Llc sold 63,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.24, for a total value of $456,120.00.
• On Friday, May 3rd, Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $7.61, for a total value of $456,600.00.
• On Wednesday, May 1st, Mva Investors, Llc sold 75,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.43, for a total transaction of $557,250.00.

Tango Therapeutics Price Performance

Shares of TNGX opened at $8.34 on Thursday. The company has a market capitalization of $891.10 million, a price-to-earnings ratio of -7.38 and a beta of 0.83. The business’s 50-day moving average is $7.87 and its 200-day moving average is $9.26. Tango Therapeutics, Inc. has a fifty-two week low of $2.88 and a fifty-two week high of $13.03.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). The company had revenue of $6.47 million during the quarter, compared to analyst estimates of $7.13 million. Tango Therapeutics had a negative return on equity of 44.35% and a negative net margin of 299.88%. Equities research analysts expect that Tango Therapeutics, Inc. will post -1.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. AJOVista LLC acquired a new position in Tango Therapeutics during the 4th quarter worth $61,000. Paloma Partners Management Co bought a new stake in Tango Therapeutics during the 1st quarter valued at approximately $80,000. Cowen AND Company LLC acquired a new stake in Tango Therapeutics in the 4th quarter valued at approximately $99,000. Price T Rowe Associates Inc. MD boosted its position in shares of Tango Therapeutics by 12.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,771 shares of the company’s stock valued at $102,000 after acquiring an additional 1,426 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Tango Therapeutics by 421.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,793 shares of the company’s stock valued at $117,000 after purchasing an additional 9,530 shares during the period. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on TNGX. Guggenheim upgraded shares of Tango Therapeutics to a “strong-buy” rating in a report on Tuesday, May 28th. Wedbush reduced their target price on Tango Therapeutics from $18.00 to $11.00 and set an “outperform” rating for the company in a report on Thursday, May 23rd. Barclays dropped their price target on Tango Therapeutics from $18.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, May 24th. Cantor Fitzgerald began coverage on shares of Tango Therapeutics in a report on Thursday, April 4th. They set an “overweight” rating on the stock. Finally, HC Wainwright decreased their price objective on shares of Tango Therapeutics from $16.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, May 28th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $14.17.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.